All News

PMR2.jpg

Is PMR the Next Indication for Tocilizumab?

d MedPage Today

About half of patients with steroid-dependent polymyalgia rheumatica (PMR) were able to get off steroids altogether when they were started on tocilizumab (Actemra) infusions, which also improved disease control in most cases, a randomized phase III trial showed.

Read Article
antibody (Keep)

Clinical Profiles Seen with NXP-2 Antibodies

d Jack Cush, MD

A recent review of the myositis associated autoantibody NXP-2 profiles its clinical associations with dermatomyositis (DM), calcinosis, severe myositis and, in some reports, with cancer.

Read Article
yoga-1240391.jpg

Yoga Fails to Benefit Knee Osteoarthritis

d Jack Cush, MD

The Annals of Internal Medicine has published a study showing online yoga education and an unsupervised yoga program may improve physical function did not improve knee pain after 12 weeks and 24 weeks.

Read Article
eye.exam_.equip_.jpg

Hydroxychloroquine Dosing and SLE Flares

d Jack Cush, MD

A cohort study examining hydroxychloroquine dosing in patients with SLE suggests that HCQ doses of 5 mg/kg per day or less, in accordance with current ophthalmology and rheumatology guidelines, was associated with a higher risk of lupus flares, including moderate or severe lupus flares.

Read Article
USA,States,map

ACR's State-by-State Report Cards for Rheumatic Disease

d Jack Cush, MD

New report examines access, affordability, and activity and lifestyle factors in all 50 states and the District of Columbia, evaluating how easy it is to live with a rheumatic disease in your state. No state scored an "A" or "F", and only two states improved their 2018 grades.

Read Article
Cohort Hip & Cohort Knee (CHECK) study of biomarkers (serum hs-CRP, sCOMP, sPINP sOC and urine uCTX-2) in1002 pts w/ hip or knee OA. Shows CRP, uCTX-2 & sPINP (OR 1.11-1.40) were assoc w/ nocturnal & walking pain, but not fatigue https://t.co/EOU6i24KLO https://t.co/VQWfeLR01x

Links:

Dr. John Cush RheumNow ( View Tweet)
Hydroxychloroquine Dosing and SLE Flares JAMA cohort study examining HCQ dosing in patients with SLE suggests that HCQ doses of 5 mg/kg per day or less, was associated with a higher risk of lupus flares, including moderate or severe lupus flares. https://t.co/B5HqxWDqD3 https://t.co/4crIFBV9XP

Links:

Dr. John Cush RheumNow ( View Tweet)
ACR's State-by-State Report Cards for Rheumatic Disease New report examines access, affordability, and activity and lifestyle factors in all 50 states and DC evaluating how easy it is to live with a rheumatic disease in your state. https://t.co/MmzG9oTfnq https://t.co/UhSM22PMf5

Links:

Dr. John Cush RheumNow ( View Tweet)
RHEUMATOLOGISTS - How do you deal with skin Psoriasis (PSO) activity in your Psoriatic Arthritis Pts?

Dr. John Cush RheumNow ( View Tweet)

#ACR22 abstracts: 0220 Do you think social media can enhance your rheuma medical education, research or professional development? @anzypanzywanzy @anjmsantiago @PhRheumaJr @rheum4you @RHEUMarampa @RheumaRambolMD @doktora_ging #ACRambassador 📌https://t.co/SZB4p0WNu8

Links:

Lisa 🐳🐬 rheumarhyme ( View Tweet)

New CDC data on vaccination/boosters during BA.5 wave for deaths, age 50+ https://t.co/HGyjNwUveD Compared w/unvaccinated: —92% reduction of death for 4 shots —No difference in reduction between 3 and 2 shots (~82%) [that's a 12-fold ⬇️risk of death for 4 shots in July 2022] https://t.co/3JDjCLbEyh

Links:

Eric Topol EricTopol ( View Tweet)
IBD Ups Risk of Psoriatic Disease Findings of a new study suggest a causal effect between inflammatory bowel disease (IBD) and psoriasis (PSO) as well as psoriatic arthritis (PsA), but not vice versa. https://t.co/twam1BcG8I https://t.co/8PFObkNn4J

Links:

Dr. John Cush RheumNow ( View Tweet)
STAR-RA study - real world claims data shows tofacitinib doesnt increase malignancy risk. Study of 83,295 pts (10,504 TOFA). Risk of malignancy w/ TOFA not increased (HR 1.01) w/ RWE or RCT-duplicate cohort (HR 1.1; 95% CI 0.85, 1.62) https://t.co/GIIvs2cK3s

Links:

Dr. John Cush RheumNow ( View Tweet)

EMA has approved 86 biosimilar medicines since 2006 and has issued a harmonizing statement for EU countries that biosimilars are interchangeable with their reference medicine or with an equivalent biosimilar. https://t.co/ajsP1ulZTQ

Links:

Dr. John Cush RheumNow ( View Tweet)

RINOMAX Trial studied single dose of 500 mg rituximab IV in myasthenia gravis - 47 MG pts randomized to RTX or PBO, after 4 mos RTX response (71% vs 29%) superior to PBO. Further studies are needed https://t.co/XvAWRH8fUz

Links:

Dr. John Cush RheumNow ( View Tweet)

Deep Vein Thrombosis reviewed in current Annals of Internal Medicine - VTE is the 3rd most common CVD, seen in 5% of population. Half of VTE assoc w/ transient preventable risk factors. Direct oral anticoagulants are effective and safer https://t.co/6utxivuwf6

Links:

Dr. John Cush RheumNow ( View Tweet)

Propensity matched pairs (n=237 872) of perioperative pts - gabapentin users and nonusers shows perioperative gabapentin use had significantly more delirium (RR 1.28), antipsychotic Rx (1.17 ) & pneumonia (1.11) vs nonusers post surgery https://t.co/UAZs7Vqy6O

Links:

Dr. John Cush RheumNow ( View Tweet)

Colchicine vs cimetidine in PFAPA (Periodic fever, aphthous stomatitis, pharyngitis, adenitis) syndrome. 72 pts given COL vs CIM x 3 mos: # of febrile attacks was significantly decreased by both Rx (noninferior to each other) https://t.co/MO7IQ0e8gf

Links:

Dr. John Cush RheumNow ( View Tweet)

Metals & Hyperuricemia (HU) (20 studies, 63,283 participants): Increased HUA risk arsenic (OR 1.7), calcium (OR 1.76), cadmium (OR 1.19), & lead (OR 1.56), BUT lower w/ molybdenum (OR  0.8). No effect w/ Cu, Fe, Mg, Zn, Cd, Co, Al, Hg, Tl https://t.co/xmdBCCBuEk

Links:

Dr. John Cush RheumNow ( View Tweet)

Burden of OA (knee, hip, hand) for India (1990 - 2019): was 23.5 million in 1990; rose to 62.35 million 2019 (prevalence of 5313 per 100,000). Most common - Knee OA > hand OA > hip OA. The prevalence was higher in females than males. https://t.co/1yMzUulBqk

Links:

Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×